---
title: 'CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after
  CD19-directed CAR T-cell therapy: a dose-finding phase 1 study'
date: '2024-07-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38996463/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240713181622&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'BACKGROUND: Outcomes are poor for patients with large B-cell lymphoma
  who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19).
  CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of
  a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown,
  which was what we aimed to examine in this ...'
disable_comments: true
---
BACKGROUND: Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown, which was what we aimed to examine in this ...